Why Life Expectancy is Reduced in ADHD

When British researchers reported in January 2025 that adults with diagnosed attention-deficit/hyperactivity disorder (ADHD) were dying about seven years earlier than their peers if male and nine years earlier if female, the finding made international headlines. A meta-analysis, a statistical pooling of many studies into one estimate, published this month in JAMA Network Open confirmed the broader pattern across nearly 16 million people:

ADHD is associated with higher death rates from every major category of cause. None measured mortality in untreated ADHD specifically, and none can say how much any single factor explains. The clinician's question is what plausibly produces the gap and what to do differently at the next visit (Barry, 2025; Corrigan et al., 2026; O'Nions et al., 2025).

The ADHD mortality gap is real; its causes are inferred

Every observational study finds higher mortality with diagnosed ADHD. Accidents, suicide, comorbidity, smoking, cardiometabolic risk, and barriers to care are plausible contributors; how much each explains, and whether ADHD itself contributes, is not established (Corrigan et al., 2026; O'Nions et al., 2025).

The headline study drew on primary care records of about 30,000 British adults with a recorded ADHD diagnosis, each matched to ten peers of the same age, sex, and practice. Using the life-table method, which applies observed death rates at each age to project how long a population will live, the investigators estimated that an 18-year-old man with diagnosed ADHD could expect to reach about 73 rather than 80, and a woman about 75 rather than 84.

These are population averages, not predictions for an individual, and the database recorded deaths without their causes. The authors' view that modifiable risks and unmet treatment needs explain the gap is a reasoned interpretation, not a tested finding (O'Nions et al., 2025).

The meta-analysis adds proportion. It reviewed 19 studies, most of them cohort studies that follow people with and without ADHD forward in time and count deaths, and could pool nine for all-cause mortality. Across those nine, the hazard of death, meaning the rate at which deaths occurred during follow-up, was roughly 1.7 times higher with ADHD.

In smaller subsets, the excess was nearly double for suicide, about one and a half times for injury, and about 1.3 times for natural causes, meaning death from disease rather than accident or self-harm. Every study pointed the same way, but effect sizes and definitions of ADHD varied widely, so the pooled figures are averages across considerable diversity (Corrigan et al., 2026).

One caveat belongs up front. Only 0.32 percent of adults in the British cohort had a recorded diagnosis, roughly one in nine of all adults with the condition, and the authors suggested this diagnosed minority may overrepresent people with co-occurring conditions and higher support needs. None of these studies isolates untreated ADHD. The figures describe diagnosed clinical populations, not everyone who screens positive on an adult questionnaire (O'Nions et al., 2025).

The shape of the risk changes with age

Accidents and suicide dominate early deaths; by mid-life, natural causes grow, and the statistical culprits are cardiovascular (Dalsgaard et al., 2015; Thapar et al., 2026).

The Danish cohort, which followed nearly two million people from their first birthday, found that accidents accounted for more than half of ADHD deaths with a known cause. The relative risk was higher in girls and women than in boys and men, higher with co-occurring conduct disorder or substance use disorder, and highest of all in those first diagnosed as adults.

People with ADHD and no comorbidity still died at an elevated rate. In absolute terms, the numbers were small, fewer than six deaths a year for every 10,000 people with ADHD, a point worth remembering when a worried parent asks (Dalsgaard et al., 2015).

The Swedish registry sharpened the picture in adults by separating causes of death and sorting comorbid conditions by when they begin. Adjusting for early-onset conditions such as autism and conduct disorder removed the link with natural-cause death; adjusting for later-onset disorders such as depression, substance use, and personality pathology removed most of the link with suicide. The link with death from unintentional injury survived full adjustment. The psychiatric conditions that travel with ADHD appear to carry much of the suicide risk, while the injury risk appears to belong to the core features of the disorder (Sun et al., 2019).

Most cohorts stop in early adulthood, which is why natural causes have been underweighted. The 1958 British birth cohort, which classified children from a handful of parent- and teacher-rated symptoms at age seven rather than a clinical diagnosis, found roughly 60 to 90 percent higher odds of premature death by 58, depending on the sample and age window.

A path analysis, a model that tests whether an association runs through intermediate variables, was consistent with indirect links through current smoking at age 42 and abdominal obesity, indexed by waist-hip ratio at age 44. These models rest on relatively few deaths and identify candidates rather than proven causes, but both candidates are measurable and treatable (Thapar et al., 2026).

Three proposed pathways from the disorder to early death

Three overlapping pathways, impulsivity, health behavior, and care, organize the evidence. The model shows where to intervene; it is not a proven causal decomposition of the deaths (Corrigan et al., 2026).

The impulsivity pathway is the most direct. Inattention and impaired response inhibition, the capacity to stop an action already underway, raise the risk of crashes, falls, poisonings, and other injuries. In more than two million American patients with ADHD, crash risk was about 40 percent lower in months when a prescription had been filled than in unmedicated months in the same person, a design that sidesteps the worry that healthier people choose treatment.

The same impulsivity, combined with emotional dysregulation, the rapid and poorly modulated emotional responses common in adult ADHD, and with depression, can turn a bad evening into a suicide attempt (Chang et al., 2017; Corrigan et al., 2026).

The health-behavior pathway takes decades to kill. Adults with diagnosed ADHD in the British cohort were about twice as likely to smoke or misuse alcohol, and the condition is consistently associated with obesity, poor diet, and disturbed sleep.

Mendelian randomization, which uses gene variants assigned at conception as a natural experiment immune to later lifestyle, supports causal effects of ADHD liability on childhood obesity, smoking initiation, and coronary artery disease, with obesity rather than smoking heaviness appearing to carry the coronary link.

In more than five million Swedish adults, those with ADHD developed cardiovascular disease at about twice the rate of those without it, an association that weakened but persisted after adjustment; that study counted new disease, not deaths (Barry, 2025; Leppert et al., 2021; Li et al., 2022; Riglin & Stergiakouli, 2022).

One hypothesis unites these behaviors without invoking weakness of character. A meta-analysis of 21 case-control studies found that people with ADHD show steeper delay discounting, valuing a reward available now far above a larger reward later. Nicotine, sugar, alcohol, and screens pay immediately; the cardiologist's advice pays off in thirty years. The mechanism has not been tied to mortality, but it makes the health profile of ADHD look like a predictable consequence of the disorder (Jackson & MacKillop, 2016).

The care pathway is the one clinicians control most directly and most easily overlook. The executive functions that ADHD impairs, namely planning, time management, sustained attention, and follow-through, are precisely what chronic disease management demands. A patient with ADHD is less likely to remember a refill, keep an appointment, finish a course of treatment, or get what is needed from a hurried 15-minute visit.

The British authors argue that health systems built for neurotypical patients systematically underserve this population, and that this inequality is malleable because it lives in the system rather than the patient (Corrigan et al., 2026; O'Nions et al., 2025).

Why women may lose more years

Women with diagnosed ADHD lose more years than men in British and Danish data. Later diagnosis, more years untreated, and a more severely affected diagnosed group are plausible explanations, but they remain untested (O'Nions et al., 2025; Rahali et al., 2026).

A recent narrative review identified female sex, delayed diagnosis, and psychiatric comorbidity as the three markers of highest mortality risk, and they are not independent. Girls with ADHD more often present with inattention than disruptive hyperactivity, are referred less often, and are diagnosed later, frequently only after depression, anxiety, or self-harm has brought them to attention.

One hypothesis is that a woman diagnosed in her thirties has carried the disorder untreated for decades and accumulated the comorbidity that drives suicide risk; the data fit that reading but do not test it. If adult diagnosis selects the most severe cases, the female-diagnosed cohort will also be skewed toward severity. The right response is earlier identification of girls and women, not alarm about the disorder's biology in females (Dalsgaard et al., 2015; O'Nions et al., 2025; Rahali et al., 2026).

Medication is associated with lower mortality

Starting medication was associated with 20 to 25 percent lower mortality, concentrated in unnatural causes. That is association, not proof, and no natural-cause effect appeared within two years (Corrigan et al., 2026; Li et al., 2024).

The most rigorous evidence is a Swedish target trial emulation, an analysis that organizes registry data to mimic a randomized trial that was never run, comparing nearly 150,000 newly diagnosed patients who started medication within three months against those who did not. Over two years, those who started died at about 80 percent of the rate of those who did not.

The association was concentrated in external causes, with accidental poisoning the likeliest contributor, and there was no overall association with natural-cause mortality in that window. The absolute difference was about nine fewer deaths per 10,000 people, because death in this young cohort is rare, and the authors called their cause-specific findings exploratory (Li et al., 2024).

The meta-analysis pooled three medication studies and found about 25 percent lower all-cause mortality, while warning that confounding by indication, the bias that arises when the reasons a clinician treats one patient and not another also affect survival, remains possible.

Two clinical points follow. The association runs through unnatural causes, so longer-term effects on the cardiovascular pathway are untested and medication alone should not be assumed to close the gap. Stimulants also modestly raise heart rate and blood pressure in a population whose cardiovascular profile is already poor, so blood pressure, weight, and smoking belong in every medication review.

Russell Barkley's analogy fits: ADHD should be managed like diabetes, a lifelong condition in which continuity and risk-factor control, not symptom relief alone, determine longevity (Barry, 2025; Corrigan et al., 2026).

Behavioral treatments act on the same pathways, with uneven evidence

No trial has tested psychotherapy, skills training, or neurofeedback against mortality. What exists is evidence that specific interventions move specific mediators (Epstein et al., 2022; Liu et al., 2023; Westwood et al., 2025).

The mortality literature is almost entirely pharmacological because registries capture every dispensed prescription and nothing about who completed therapy. That is a feature of the data, not evidence that behavioral treatment is irrelevant. The pathways above are behavioral at every step: a crash, an impulsive overdose, a cigarette, a missed appointment. Any intervention that durably improves attention, impulse control, emotion regulation, or organization acts on the same mediators medication does, and the question is which ones have been shown to (Corrigan et al., 2026).

Cognitive behavioral therapy (CBT), a structured skills-based psychotherapy, has the strongest record. In a landmark trial, medicated adults with persistent symptoms were randomized to 12 sessions of CBT or an equally intensive relaxation program, rated by assessors blind to treatment; just over half of CBT patients responded against under a quarter of controls, and the gains held for a year.

A meta-analysis of 28 randomized trials found that CBT also reduces depression and anxiety, which matters because depression carried most of the suicide risk in the Swedish data.

Skills groups built on dialectical behavior therapy (DBT), which teaches mindfulness, distress tolerance, and emotion regulation, target the care pathway: a seven-site Norwegian trial of 121 adults found larger gains than usual care in executive function, symptoms, depression, and quality of life after 14 weeks, though not in anxiety or emotion regulation itself, with gains persisting at an uncontrolled six-month follow-up (Halmøy et al., 2022; Liu et al., 2023; Safren et al., 2010; Sun et al., 2019).

The evidence is thinner for the health-behavior pathway: most smoking-cessation programs adapted for ADHD have not improved quit rates, and no ADHD-specific program has yet beaten standard care for weight.

The clearest demonstration that a brief behavioral intervention can reduce a direct precursor of ADHD mortality comes from driving. In a New England Journal of Medicine trial, 152 adolescents received five sessions of computer and simulator training that sounded an alarm whenever their eyes left the road for more than two seconds. Over the following year, in-vehicle cameras recorded about 24 percent fewer long glances during hard braking and turning, and about 40 percent fewer crashes and near-crashes (Epstein et al., 2022; Thapar et al., 2026).

The behavioral evidence shares durability: medication's protection was measured only while prescriptions were filled, while learned skills persist. That is an argument from logic, not a demonstrated outcome (Arns et al., 2014; Van Doren et al., 2019; Westwood et al., 2025).

What this means at the point of care

Treat ADHD as a mortality risk factor, consider assessment when refractory smoking, weight, injuries, or missed care meet a lifelong history of inattention, and redesign the encounter so patients can follow through (Barry, 2025; Thapar et al., 2026).

Consider the adult who has failed three attempts to quit smoking, cannot keep weight off, misses half his appointments, and has had two emergency visits for injuries this year. The conventional reading is poor motivation. Screening for ADHD on that pattern alone is not validated, but in a patient with a lifelong history of inattention, impulsivity, and impairment it should prompt diagnostic assessment, because treating the disorder may be the precondition for everything else working.

Barkley has argued this for years, and the 1958 cohort supports it: in mid-life, smoking and abdominal obesity are candidate mechanisms, and both are plausibly more tractable when attention and impulse control improve (Barry, 2025; Thapar et al., 2026).

For patients already diagnosed, the literature suggests a short list for every visit. Ask directly about suicidal thinking, especially around substance use, relationship crisis, or lapsed medication, since suicidal acts in this population are often impulsive. Ask about driving and whether medication coverage extends into the hours the patient actually drives. Measure blood pressure and waist circumference, record smoking status, and apply standard cardiovascular prevention with individualized risk assessment. Review whether the patient is taking medications prescribed for other conditions; executive difficulties contribute to missed care, and so do cost, access, side effects, and preference (Chang et al., 2017; Sun et al., 2019; Thapar et al., 2026).

The encounter itself can be adapted with written instructions, a single next step rather than a list, same-day text reminders, shorter and more frequent visits, and a standing annual physical health check, which the 1958 cohort investigators have proposed incentivizing in primary care.

The treatment plan should be layered to match the pathways. Medication addresses the unnatural-cause risk, where it alone has mortality data; CBT or a DBT-based group addresses the depression and executive deficits that feed the suicide and care pathways; targeted work covers driving, sleep, smoking, and weight.

Integrative summary

Adults with diagnosed ADHD die several years earlier than their peers in observational studies, and accidents, suicide, substance use, smoking, obesity, and poorly managed medical conditions are plausible but unquantified contributors. Unnatural causes dominate early deaths, and medication is associated with fewer of them; natural causes grow in mid-life, where smoking and abdominal obesity are the leading candidates.

CBT and skills groups improve depression and executive deficits on the suicide and care pathways; driver training has reduced real-world crashes, and neurofeedback's symptom evidence remains contested. The clinical response is early identification, layered treatment, routine cardiovascular and suicide risk review, and care adapted to patients whose disorder undermines follow-through (Corrigan et al., 2026; O'Nions et al., 2025; Thapar et al., 2026).”

Key takeaways

1. Diagnosed ADHD is associated with a seven-to-nine-year shorter life expectancy and about a 70 percent higher death hazard; how much is modifiable, and how much the disorder itself contributes, is not established.

2. Accidents and suicide dominate early deaths; in mid-life, smoking and abdominal obesity are the leading candidate explanations.

3. Women, adults diagnosed late, and patients with psychiatric comorbidity carry the highest risk.

4. Medication is associated with lower short-term mortality from unnatural causes; CBT, DBT-based groups, and driver-attention training improve mortality-relevant mediators.

5. Consider diagnostic assessment when refractory smoking, weight, injuries, or missed care meet a lifelong history of inattention and impulsivity, and build the visit around the patient's executive deficits.

Glossary

attention-deficit/hyperactivity disorder (ADHD): a neurodevelopmental condition of persistent inattention and/or hyperactivity-impulsivity that impairs functioning.

biofeedback: training in which an instrument displays a physiological process so that voluntary control can be learned.

cognitive behavioral therapy (CBT): a structured psychotherapy that teaches skills for changing the thoughts and behaviors that maintain a problem.

cohort study: an observational study that follows a group over time and compares outcomes by exposure.

confounding by indication: bias that arises when the factors that lead a clinician to prescribe a treatment also affect the outcome.

delay discounting: the tendency to devalue a reward as the delay to receiving it grows.

dialectical behavior therapy (DBT): a skills-based therapy that teaches mindfulness, distress tolerance, emotion regulation, and interpersonal effectiveness.

emotional dysregulation: difficulty modulating the intensity and duration of emotional responses.

executive functions: the cognitive processes that organize goal-directed behavior: planning, working memory, inhibition, sustained attention.

life table: an actuarial method that applies age-specific death rates to estimate expected remaining years of life.

Mendelian randomization: a method that uses inherited gene variants to test whether an exposure causally affects an outcome.

meta-analysis: a statistical combination of results from multiple studies to produce a pooled estimate.

neurofeedback: biofeedback of brain activity, usually EEG, so that the client can learn to alter it.

path analysis: a statistical method that tests whether an association between an exposure and an outcome runs directly or through one or more intermediate variables, estimating the strength of each link in the proposed chain.

target trial emulation: an analytic framework that structures observational data to mimic a hypothetical randomized trial.

References

Arns, M., Feddema, I., & Kenemans, J. L. (2014). Differential effects of theta/beta and SMR neurofeedback in ADHD on sleep onset latency. Frontiers in Human Neuroscience, 8, Article 1019. https://doi.org/10.3389/fnhum.2014.01019

Barry, E. (2025, January 23). People with A.D.H.D. are likely to die significantly earlier than their peers, study finds. The New York Times. https://www.nytimes.com/2025/01/23/health/adhd-life-expectancy.html

Chang, Z., Quinn, P. D., Hur, K., Gibbons, R. D., Sjölander, A., Larsson, H., & D'Onofrio, B. M. (2017). Association between medication use for attention-deficit/hyperactivity disorder and risk of motor vehicle crashes. JAMA Psychiatry, 74(6), 597–603. https://doi.org/10.1001/jamapsychiatry.2017.0659

Corrigan, L., Heywood, L., Stewart, G. R., O'Nions, E., Shelford, H., Stott, J., & John, A. (2026). Mortality among people with attention-deficit/hyperactivity disorder: A systematic review and meta-analysis. JAMA Network Open, 9(10), Article e2639448. https://doi.org/10.1001/jamanetworkopen.2026.39448

Dalsgaard, S., Østergaard, S. D., Leckman, J. F., Mortensen, P. B., & Pedersen, M. G. (2015). Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: A nationwide cohort study. The Lancet, 385(9983), 2190–2196. https://doi.org/10.1016/S0140-6736(14)61684-6

Epstein, J. N., Garner, A. A., Kiefer, A. W., Peugh, J., Tamm, L., MacPherson, R. P., Simon, J. O., & Fisher, D. L. (2022). Trial of training to reduce driver inattention in teens with ADHD. The New England Journal of Medicine, 387(22), 2056–2066. https://doi.org/10.1056/NEJMoa2204783

Halmøy, A., Ring, A. E., Gjestad, R., Møller, M., Ubostad, B., Lien, T., Munkhaugen, E. K., & Fredriksen, M. (2022). Dialectical behavioral therapy-based group treatment versus treatment as usual for adults with attention-deficit hyperactivity disorder: A multicenter randomized controlled trial. BMC Psychiatry, 22, Article 738. https://doi.org/10.1186/s12888-022-04356-6

Jackson, J. N. S., & MacKillop, J. (2016). Attention-deficit/hyperactivity disorder and monetary delay discounting: A meta-analysis of case-control studies. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 1(4), 316–325. https://doi.org/10.1016/j.bpsc.2016.01.007

Leppert, B., Riglin, L., Wootton, R. E., Dardani, C., Thapar, A. K., Staley, J. R., Tilling, K., Davey Smith, G., Thapar, A., & Stergiakouli, E. (2021). The effect of attention deficit/hyperactivity disorder on physical health outcomes: A 2-sample Mendelian randomization study. American Journal of Epidemiology, 190(6), 1047–1055. https://doi.org/10.1093/aje/kwaa273

Li, L., Chang, Z., Sun, J., Garcia-Argibay, M., Du Rietz, E., Dobrosavljevic, M., Brikell, I., Jernberg, T., Solmi, M., Cortese, S., & Larsson, H. (2022). Attention-deficit/hyperactivity disorder as a risk factor for cardiovascular diseases: A nationwide population-based cohort study. World Psychiatry, 21(3), 452–459. https://doi.org/10.1002/wps.21020

Li, L., Zhu, N., Zhang, L., Kuja-Halkola, R., D'Onofrio, B. M., Brikell, I., Lichtenstein, P., Cortese, S., Larsson, H., & Chang, Z. (2024). ADHD pharmacotherapy and mortality in individuals with ADHD. JAMA, 331(10), 850–860. https://doi.org/10.1001/jama.2024.0851

Liu, C. I., Hua, M. H., Lu, M. L., & Goh, K. K. (2023). Effectiveness of cognitive behavioural-based interventions for adults with attention-deficit/hyperactivity disorder extends beyond core symptoms: A meta-analysis of randomized controlled trials. Psychology and Psychotherapy: Theory, Research and Practice, 96(3), 543–559. https://doi.org/10.1111/papt.12455

O'Nions, E., El Baou, C., John, A., Lewer, D., Mandy, W., McKechnie, D. G. J., Petersen, I., & Stott, J. (2025). Life expectancy and years of life lost for adults with diagnosed ADHD in the UK: Matched cohort study. The British Journal of Psychiatry, 226(5), 261–268. https://doi.org/10.1192/bjp.2024.199

Rahali, Y., Dennison, C. A., Thapar, A., & Thapar, A. K. (2026). Attention deficit hyperactivity disorder (ADHD) and premature mortality: A narrative review of the literature. European Child & Adolescent Psychiatry. Advance online publication. https://doi.org/10.1007/s00787-026-03156-7

Riglin, L., & Stergiakouli, E. (2022). Mendelian randomisation studies of attention deficit hyperactivity disorder. JCPP Advances, 2(4), Article e12117. https://doi.org/10.1002/jcv2.12117

Safren, S. A., Sprich, S., Mimiaga, M. J., Surman, C., Knouse, L., Groves, M., & Otto, M. W. (2010). Cognitive behavioral therapy vs relaxation with educational support for medication-treated adults with ADHD and persistent symptoms: A randomized controlled trial. JAMA, 304(8), 875–880. https://doi.org/10.1001/jama.2010.1192

Sun, S., Kuja-Halkola, R., Faraone, S. V., D'Onofrio, B. M., Dalsgaard, S., Chang, Z., & Larsson, H. (2019). Association of psychiatric comorbidity with the risk of premature death among children and adults with attention-deficit/hyperactivity disorder. JAMA Psychiatry, 76(11), 1141–1149. https://doi.org/10.1001/jamapsychiatry.2019.1944

Thapar, A. K., Collishaw, S., Davey Smith, G., Stergiakouli, E., & Thapar, A. (2026). Association between childhood ADHD problems and premature mortality: Identifying modifiable cardiovascular mechanisms in a UK population cohort. Frontiers in Psychiatry, 17, Article 1764335. https://doi.org/10.3389/fpsyt.2026.1764335

Van Doren, J., Arns, M., Heinrich, H., Vollebregt, M. A., Strehl, U., & Loo, S. K. (2019). Sustained effects of neurofeedback in ADHD: A systematic review and meta-analysis. European Child & Adolescent Psychiatry, 28(3), 293–305. https://doi.org/10.1007/s00787-018-1121-4

Westwood, S. J., Aggensteiner, P.-M., Kaiser, A., Nagy, P., Donno, F., Merkl, D., Balia, C., Goujon, A., Bousquet, E., Capodiferro, A. M., Derks, L., Purper-Ouakil, D., Carucci, S., Holtmann, M., Brandeis, D., Cortese, S., & Sonuga-Barke, E. J. S. (2025). Neurofeedback for attention-deficit/hyperactivity disorder: A systematic review and meta-analysis. JAMA Psychiatry, 82(2), 118–129. https://doi.org/10.1001/jamapsychiatry.2024.3702